Suppr超能文献

免疫记忆细胞作为多发性硬化症治疗靶点的作用

Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis.

作者信息

Bose Tanima

机构信息

Institute of Human Genetics, University of Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany.

出版信息

Brain Sci. 2017 Nov 7;7(11):148. doi: 10.3390/brainsci7110148.

Abstract

Pharmacological targeting of memory cells is an attractive treatment strategy in various autoimmune diseases, such as psoriasis and rheumatoid arthritis. Multiple sclerosis is the most common inflammatory disorder of the central nervous system, characterized by focal immune cell infiltration, activation of microglia and astrocytes, along with progressive damage to myelin sheaths, axons, and neurons. The current review begins with the identification of memory cell types in the previous literature and a recent description of the modulation of these cell types in T, B, and resident memory cells in the presence of different clinically approved multiple sclerosis drugs. Overall, this review paper tries to determine the potential of memory cells to act as a target for the current or newly-developed drugs.

摘要

在各种自身免疫性疾病,如银屑病和类风湿性关节炎中,对记忆细胞进行药理学靶向治疗是一种有吸引力的治疗策略。多发性硬化症是中枢神经系统最常见的炎症性疾病,其特征是局部免疫细胞浸润、小胶质细胞和星形胶质细胞活化,以及髓鞘、轴突和神经元的进行性损伤。本综述首先在以往文献中识别记忆细胞类型,并描述了在不同临床批准的多发性硬化症药物存在的情况下,这些细胞类型在T细胞、B细胞和驻留记忆细胞中的调节情况。总体而言,本综述试图确定记忆细胞作为当前或新开发药物靶点的潜力。

相似文献

1
Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis.
Brain Sci. 2017 Nov 7;7(11):148. doi: 10.3390/brainsci7110148.
2
Neuronal injury in chronic CNS inflammation.
Best Pract Res Clin Anaesthesiol. 2010 Dec;24(4):551-62. doi: 10.1016/j.bpa.2010.11.001. Epub 2010 Nov 29.
3
Pathogenic role of tissue-resident memory T cells in autoimmune diseases.
Autoimmun Rev. 2018 Sep;17(9):906-911. doi: 10.1016/j.autrev.2018.03.014. Epub 2018 Jul 10.
4
Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
Biochim Biophys Acta. 2016 Mar;1862(3):461-71. doi: 10.1016/j.bbadis.2015.10.018. Epub 2015 Oct 23.
5
Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells.
Front Immunol. 2018 Jun 18;9:1347. doi: 10.3389/fimmu.2018.01347. eCollection 2018.
6
The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
Cells. 2019 Aug 3;8(8):825. doi: 10.3390/cells8080825.
7
Autoimmune disease in the brain--how to spot the culprits and how to keep them in check.
J Neurol Sci. 2011 Dec;311 Suppl 1:S3-11. doi: 10.1016/S0022-510X(11)70002-8.
8
The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
Ann Neurol. 2009 Mar;65(3):239-48. doi: 10.1002/ana.21640.
9
Increased CD8+ central memory T cells in patients with multiple sclerosis.
Mult Scler. 2007 Mar;13(2):149-55. doi: 10.1177/1352458506069246. Epub 2007 Jan 29.
10
CD8 Resident Memory T Cells and Viral Infection.
Front Immunol. 2018 Sep 19;9:2093. doi: 10.3389/fimmu.2018.02093. eCollection 2018.

引用本文的文献

1
Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.
Front Immunol. 2020 Jan 31;11:56. doi: 10.3389/fimmu.2020.00056. eCollection 2020.
2
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.
Trends Mol Med. 2020 Mar;26(3):296-310. doi: 10.1016/j.molmed.2019.11.003. Epub 2019 Dec 17.
3
X-tra X: An escape to autoimmunity.
J Clin Invest. 2019 Aug 12;129(9):3536-3538. doi: 10.1172/JCI130312.
4
Emerging small-molecule treatments for multiple sclerosis: focus on B cells.
F1000Res. 2019 Mar 1;8. doi: 10.12688/f1000research.16495.1. eCollection 2019.
5
Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.
CNS Drugs. 2018 Nov;32(11):1039-1051. doi: 10.1007/s40263-018-0567-8.
6
Pathophysiology and Imaging Diagnosis of Demyelinating Disorders.
Brain Sci. 2018 Mar 14;8(3):44. doi: 10.3390/brainsci8030044.

本文引用的文献

1
Teriflunomide treatment reduces B cells in patients with MS.
Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e403. doi: 10.1212/NXI.0000000000000403. eCollection 2017 Nov.
2
Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
J Immunol. 2017 Apr 15;198(8):3069-3080. doi: 10.4049/jimmunol.1601532. Epub 2017 Mar 3.
4
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.
EBioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31.
5
Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14.
6
CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics.
J Immunol. 2016 Dec 1;197(11):4257-4265. doi: 10.4049/jimmunol.1600782. Epub 2016 Oct 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验